PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.30%
Under 50% of Drug Manufacturers - Specialty & Generic median of 46.37% if negative or far above if positive. Jim Chanos would sense potential red flags or large tie-ups in these rarely monitored accounts.
77.70%
A moderate rise while Drug Manufacturers - Specialty & Generic median is negative at -18.65%. Peter Lynch might see peers cleaning up intangible or one-time items more aggressively.
85.85%
Operating cash flow growth near Drug Manufacturers - Specialty & Generic median of 85.85%. Charlie Munger would find it typical for this stage in the industry cycle.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.89%
Under 50% of Drug Manufacturers - Specialty & Generic median of 98.89% if negative or well above if positive. Jim Chanos would suspect a large mismatch or potential waste if outflows are too high vs. peers.
98.89%
Under 50% of Drug Manufacturers - Specialty & Generic median of 92.99% if negative or well above if positive. Jim Chanos sees potential overspending or major liquidity drain overshadowing typical sector levels.
-48.35%
Debt repayment yoy declines while Drug Manufacturers - Specialty & Generic median is -48.35%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
-37.35%
We reduce issuance yoy while Drug Manufacturers - Specialty & Generic median is -37.35%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.